MMJ BioPharma Cultivation Exposé
Newly uncovered DEA agreements confirm that the agency's own rules make it impossible for any company to legally produce pharmaceutical grade cannabis for FDA authorized clinical research.
A recently disclosed memorandum of understanding between the DEA and a registered marijuana cultivator has revealed a fatal flaw at the heart of America's cannabis research policy.
MMJ BioPharma Cultivation has argued for years that the DEA's rules make it impossible to legally produce pharmaceutical grade cannabis.
This revelation supports MMJ BioPharma Cultivation's case and exposes why legitimate science has been paralyzed for nearly a decade.
Author's summary: DEA's rules hinder cannabis research.
More News
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- West Indies ease past Bangladesh in first T20I
- 'Google Guys’ back on top: Larry Page, Sergey Brin grow $50 billion richer, close in on Larry Ellison’s lead - Trending News | The Financial Express
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Three resilient UK multinationals global managers are excited about | Trustnet
- 5 members of the 2025 Yankees make list of top 50 free agents
- Meralco profit jumps 14% to P40 billion in 9 months
- Pangilinan says Meralco on track to hit P50-billion profit target - BusinessWorld Online
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow